Gain Therapeutics (NASDAQ:GANX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Gain Therapeutics (NASDAQ:GANX) posted its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07, Zacks reports.

Gain Therapeutics Price Performance

NASDAQ:GANX traded down $0.09 during midday trading on Friday, hitting $1.98. The company had a trading volume of 106,033 shares, compared to its average volume of 280,021. The stock’s fifty day moving average price is $2.23 and its 200-day moving average price is $2.05. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.04. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $52.52 million, a PE ratio of -1.80 and a beta of 0.14.

Analysts Set New Price Targets

A number of analysts have commented on GANX shares. Scotiabank assumed coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, March 17th. Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Friday. Roth Mkm reiterated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Gain Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.